EQUITY RESEARCH MEMO
Statecs
Generated 5/9/2026
Executive Summary
Conviction (model self-assessment)45/100
Statecs is a Swiss Contract Research Organization (CRO) and software company founded in 2005, headquartered in Basel. It provides clinical trial management and regulatory compliance solutions for the pharmaceutical industry, leveraging digital health and AI/machine learning to enhance clinical research efficiency. As a private company with no disclosed funding or valuation, Statecs operates in a competitive European market. Despite limited public visibility, its long-standing presence and focus on AI-driven CRO services position it to capitalize on growing demand for tech-enabled clinical trials. However, lack of recent milestones or commercial traction suggests a need for differentiation and market penetration.
Upcoming Catalysts (preview)
- TBDStrategic partnership with a top-20 pharma company for AI-powered trial management30% success
- Q3 2026Launch of a new regulatory compliance module featuring real-time AI analytics50% success
- Q4 2026Expansion into EU markets with local data sovereignty solutions40% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)